Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer

Journal of Proteome Research

Volumn 10, Issue 7, 2011, Pages 3200-3211

  Organ, Shawna L ^a,b   Tong, Jiefei ^c   Taylor, Paul ^c   St Germain, Jonathan R ^c,d   Navab, Roya ^a   Moran, Michael F ^c,d   Tsao, Ming Sound ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ARTICLE; CARCINOGENESIS; COLORECTAL CANCER; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; TUMOR GROWTH;

BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; COLORECTAL NEOPLASMS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOPRECIPITATION; PHOSPHOPROTEINS; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN KINASE INHIBITORS; PROTEOME; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TANDEM MASS SPECTROMETRY;

EID: 79960000828     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr200238t     Document Type: Article

References (88)

1. Canadian Cancer Society's Steering Committee; Canadian Cancer Statistics 2010 Toronto: Canadian Cancer Society, 2010.
2. Liu, C.; Park, M.; Tsao, M. S. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas Oncogene 1992, 7 (1) 181-5
3. Fujita, S.; Sugano, K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases Jpn. J. Clin. Oncol. 1997, 27 (6) 378-83 (Pubitemid 127519258)
4. Hiscox, S. E. Expression of the HGF/SF receptor, c-met, and its ligand in human colorectal cancers Cancer Invest. 1997, 15 (6) 513-21 (Pubitemid 28015594)
5. Di Renzo, M. F. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer Clin. Cancer Res. 1995, 1 (2) 147-54
6. Fazekas, K. Experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis Clin. Exp. Metastasis 2000, 18 (8) 639-49 (Pubitemid 34056320)
7. Takeuchi, H. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases Clin. Cancer Res. 2003, 9 (4) 1480-8 (Pubitemid 36418405)
8. Comoglio, P. M.; Di Renzo, M. F.; Gaudino, G. Protein tyrosine kinases associated with human malignancies Ann. N.Y. Acad. Sci. 1987, 511, 256-61 (Pubitemid 18093048)
9. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling Nature 2001, 411 (6835) 355-65 (Pubitemid 32467045)
10. Olsen, J. V. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks Cell 2006, 127 (3) 635-48 (Pubitemid 44647421)
11. Rush, J. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells Nat. Biotechnol. 2005, 23 (1) 94-101 (Pubitemid 41724631)
12. Huang, P. H. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (31) 12867-72 (Pubitemid 47255246)
13. St-Germain, J. R. Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (47) 20127-32
14. Blagoev, B. Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics Nat. Biotechnol. 2004, 22 (9) 1139-45 (Pubitemid 39166852)
15. Dengjel, J. Quantitative proteomic assessment of very early cellular signaling events Nat. Biotechnol. 2007, 25 (5) 566-8 (Pubitemid 46834842)
16. Wolf-Yadlin, A. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (14) 5860-5 (Pubitemid 47175624)
17. Wu, S. L. Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA) Mol. Cell. Proteomics 2006, 5 (9) 1610-27
18. Zhang, Y. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules Mol. Cell. Proteomics 2005, 4 (9) 1240-50 (Pubitemid 41448712)
19. Stover, D. R. Differential phosphoprofiles of egf and egfr kinase inhibitor-treated human tumor cells and mouse xenografts Clin. Proteomics 2004, 1 (1) 69-80 (Pubitemid 41271311)
20. Trusolino, L.; Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth Nat. Rev. Cancer 2002, 2 (4) 289-300 (Pubitemid 37328782)
21. Naldini, L. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor Embo J. 1991, 10 (10) 2867-78 (Pubitemid 21905304)
22. Weidner, K. M.; Sachs, M.; Birchmeier, W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells J. Cell Biol. 1993, 121 (1) 145-54 (Pubitemid 23097370)
23. Rodrigues, G. A.; Park, M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase Oncogene 1994, 9 (7) 2019-27 (Pubitemid 24194169)
24. Ponzetto, C. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family Cell 1994, 77 (2) 261-71 (Pubitemid 24138623)
25. Birchmeier, C. Met, metastasis, motility and more Nat. Rev. Mol. Cell. Biol. 2003, 4 (12) 915-25 (Pubitemid 37493640)
26. Jeffers, M. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway Mol. Cell. Biol. 1997, 17 (2) 799-808 (Pubitemid 27044379)
27. Nakamura, Y. Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines Cancer Sci. 2008, 99 (1) 14-22 (Pubitemid 350239026)
28. Shinomiya, N. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival Cancer Res. 2004, 64 (21) 7962-70 (Pubitemid 39446930)
29. Matsumoto, K.; Nakamura, T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions Int. J. Cancer 2006, 119 (3) 477-83 (Pubitemid 43955698)
30. Navab, R. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells Neoplasia 2009, 11 (12) 1292-300
31. Shirasawa, S. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras Science 1993, 260 (5104) 85-8 (Pubitemid 23122749)
32. Long, I. S. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo Mol. Cancer Res. 2003, 1 (5) 393-401 (Pubitemid 36437925)
33. Beausoleil, S. A. A probability-based approach for high-throughput protein phosphorylation analysis and site localization Nat. Biotechnol. 2006, 24 (10) 1285-92 (Pubitemid 44564776)
34. Searle, B. C. Scaffold: a bioinformatic tool for validating MS/MS-based proteomic studies Proteomics 2010, 10 (6) 1265-9
35. Keller, A. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search Anal. Chem. 2002, 74 (20) 5383-92 (Pubitemid 35215372)
36. Tsou, C. C. IDEAL-Q, an automated tool for label-free quantitation analysis using an efficient peptide alignment approach and spectral data validation Mol. Cell. Proteomics 2010, 9 (1) 131-44
37. Schwartz, D.; Gygi, S. P. An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets Nat. Biotechnol. 2005, 23 (11) 1391-8 (Pubitemid 41679391)
38. Amanchy, R. A curated compendium of phosphorylation motifs Nat. Biotechnol. 2007, 25 (3) 285-6
39. Brown, K. R.; Jurisica, I. Online predicted human interaction database Bioinformatics 2005, 21 (9) 2076-82 (Pubitemid 40668047)
40. Brown, K. R.; Jurisica, I. Unequal evolutionary conservation of human protein interactions in interologous networks Genome Biol. 2007, 8 (5) R95
41. Brown, K. R. NAViGaTOR: Network Analysis, Visualization and Graphing Toronto Bioinformatics 2009, 25 (24) 3327-9
42. Sachs, M. Essential role of Gab1 for signaling by the c-Met receptor in vivo J. Cell Biol. 2000, 150 (6) 1375-84
43. Guo, A. Signaling networks assembled by oncogenic EGFR and c-Met Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (2) 692-7 (Pubitemid 351171770)
44. Hammond, D. E. Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks J. Proteome Res. 2010, 9 (5) 2734-42
45. Wei, Y. Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures J. Proteome Res. 2011, 10 (1) 161-74
46. Kruger, M. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function Cell 2008, 134 (2) 353-64 (Pubitemid 352010327)
47. Wu, C. C. Metabolic labeling of mammalian organisms with stable isotopes for quantitative proteomic analysis Anal. Chem. 2004, 76 (17) 4951-9 (Pubitemid 39180319)
48. Shin, N. Y. Subsets of the major tyrosine phosphorylation sites in Crk-associated substrate (CAS) are sufficient to promote cell migration J. Biol. Chem. 2004, 279 (37) 38331-7
49. Seiden-Long, I. Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells Carcinogenesis 2008, 29 (3) 647-55 (Pubitemid 351404883)
50. Chan, P. C. Differential phosphorylation of the docking protein Gab1 by c-Src and the hepatocyte growth factor receptor regulates different aspects of cell functions Oncogene 2010, 29 (5) 698-710
51. Cunningham, D. L. Differential phosphoproteomics of fibroblast growth factor signaling: identification of Src family kinase-mediated phosphorylation events J. Proteome Res. 2010, 9 (5) 2317-28
52. Knowlton, M. L. Profiling Y561-dependent and -independent substrates of CSF-1R in epithelial cells PLoS One 2010, 5 (10) e13587
53. Leroy, C. Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells Cancer Res. 2009, 69 (6) 2279-86
54. Luo, W. Global impact of oncogenic Src on a phosphotyrosine proteome J. Proteome Res. 2008, 7 (8) 3447-60
55. Weng, Z. Detection of Src homology 3-binding proteins, including paxillin, in normal and v-Src-transformed Balb/c 3T3 cells J. Biol. Chem. 1993, 268 (20) 14956-63 (Pubitemid 23206644)
56. Karlsson, T. Molecular interactions of the Src homology 2 domain protein Shb with phosphotyrosine residues, tyrosine kinase receptors and Src homology 3 domain proteins Oncogene 1995, 10 (8) 1475-83
57. Roof, R. W. Phosphotyrosine (p-Tyr)-dependent and -independent mechanisms of p190 RhoGAP-p120 RasGAP interaction: Tyr 1105 of p190, a substrate for c-Src, is the sole p-Tyr mediator of complex formation Mol. Cell. Biol. 1998, 18 (12) 7052-63 (Pubitemid 28533025)
58. Aligayer, H. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis Cancer 2002, 94 (2) 344-51
59. Cartwright, C. A. pp60c-src activation in human colon carcinoma J. Clin. Invest. 1989, 83 (6) 2025-33 (Pubitemid 19148875)
60. Han, N. M.; Curley, S. A.; Gallick, G. E. Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases Clin. Cancer Res. 1996, 2 (8) 1397-404 (Pubitemid 26299440)
61. Park, J.; Meisler, A. I.; Cartwright, C. A. c-Yes tyrosine kinase activity in human colon carcinoma Oncogene 1993, 8 (10) 2627-35 (Pubitemid 23279090)
62. Saito, Y. D. Fyn: a novel molecular target in cancer Cancer 2010, 116 (7) 1629-37
63. Veillette, A. Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines Oncogene Res. 1987, 1 (4) 357-74 (Pubitemid 18046337)
64. Subramaniam, V. CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation Exp. Mol. Pathol. 2007, 83 (2) 207-15 (Pubitemid 47320661)
65. Jin, L. L. Measurement of protein phosphorylation stoichiometry by selected reaction monitoring mass spectrometry J. Proteome Res. 2010, 9 (5) 2752-61
66. Stover, D. R.; Furet, P.; Lydon, N. B. Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain J. Biol. Chem. 1996, 271 (21) 12481-7 (Pubitemid 26160919)
67. Moarefi, I. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement Nature 1997, 385 (6617) 650-3 (Pubitemid 27087580)
68. Sicheri, F.; Kuriyan, J. Structures of Src-family tyrosine kinases Curr. Opin. Struct. Biol. 1997, 7 (6) 777-85 (Pubitemid 28025103)
69. Brauer, P. M.; Tyner, A. L. RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK Cell Cycle 2009, 8 (17) 2728-32
70. Rahimi, N. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells J. Biol. Chem. 1998, 273 (50) 33714-21 (Pubitemid 29005761)
71. Emaduddin, M. Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (7) 2358-62 (Pubitemid 351520518)
72. Hanke, J. H. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation J. Biol. Chem. 1996, 271 (2) 695-701
73. Christensen, J. G. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo Cancer Res. 2003, 63 (21) 7345-55 (Pubitemid 37413476)
74. Hui, A. Y. Src and FAK mediate cell-matrix adhesion-dependent activation of Met during transformation of breast epithelial cells J. Cell. Biochem. 2009, 107 (6) 1168-81
75. Lanzetti, L. The Eps8 protein coordinates EGF receptor signalling through Rac and trafficking through Rab5 Nature 2000, 408 (6810) 374-7
76. Martinu, L. Endocytosis of epidermal growth factor receptor regulated by Grb2-mediated recruitment of the Rab5 GTPase-activating protein RN-tre J. Biol. Chem. 2002, 277 (52) 50996-1002 (Pubitemid 36042270)
77. Tall, G. G. Ras-activated endocytosis is mediated by the Rab5 guanine nucleotide exchange activity of RIN1 Dev. Cell 2001, 1 (1) 73-82 (Pubitemid 33586070)
78. Bolen, J. B. Activation of pp60c-src protein kinase activity in human colon carcinoma Proc. Natl. Acad. Sci. U.S.A. 1987, 84 (8) 2251-5 (Pubitemid 17075849)
79. Dehm, S. M.; Bonham, K. SRC gene expression in human cancer: the role of transcriptional activation Biochem. Cell Biol. 2004, 82 (2) 263-74 (Pubitemid 38680178)
80. Termuhlen, P. M. Site-specific differences in pp60c-src activity in human colorectal metastases J. Surg. Res. 1993, 54 (4) 293-8 (Pubitemid 23235765)
81. Lieu, C.; Kopetz, S. The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy Clin. Colorectal Cancer 2010, 9 (2) 89-94
82. Yoshida, T. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification Cancer Sci. 2010, 101 (1) 167-72
83. Sunitha, I. A src-related kinase in the brush border membranes of gastrointestinal cells is regulated by c-met Exp. Cell Res. 1999, 250 (1) 86-98 (Pubitemid 29391573)
84. Castro, N. E.; Lange, C. A. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells Breast Cancer Res. 2010, 12 (4) R60
85. Karihaloo, A. Differential MAPK pathways utilized for HGF- and EGF-dependent renal epithelial morphogenesis J. Biol. Chem. 2001, 276 (12) 9166-73
86. Ramos-Nino, M. E. HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway Am. J. Respir. Cell Mol. Biol. 2008, 38 (2) 209-17 (Pubitemid 351162843)
87. Schiller, J. H., Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). In J. Clin. Oncol. (Meeting Abstracts), ASCO Annual Meeting Proceedings (Post-Meeting Edition), June 2010.
88. Yeatman, T. J. A renaissance for SRC Nat. Rev. Cancer 2004, 4 (6) 470-80 (Pubitemid 38745532)